CDC20 and prostate carcinoma: Moreover, we demonstrate that depletion of CDC20 by shRNA constructs or small molecular inhibitors significantly enhances the anti-tumor immunity dependent on the existence of GSDME in prostate cancer and exhibits synergistic effects when combined with α-PD-1 therapy.